MOG (35-55): Benchmark Peptide for Experimental Autoimmune Encephalomyelitis Research

Executive Summary: MOG (35-55) is a truncated peptide from human myelin oligodendrocyte glycoprotein, widely utilized as an inducer of experimental autoimmune encephalomyelitis (EAE), the standard animal model for multiple sclerosis (MS) research (Xu et al., 2025). The peptide reliably triggers robust T and B cell-mediated immune responses, leading to demyelination and relapsing-remitting neurological symptoms in rodents. In vivo, MOG (35-55) administration at 50–150 μg per mouse (subcutaneously, with CFA) induces MS-like pathology, with dose-dependent severity. In vitro, the peptide modulates oxidative stress and matrix remodeling pathways by increasing NADPH oxidase and MMP-9 activities. The product is supplied by APExBIO (SKU: A8306), with validated solubility and storage guidelines ensuring reproducible outcomes (product page).

Biological Rationale

MOG (35-55) is derived from amino acids 35 to 55 of the human myelin oligodendrocyte glycoprotein, a CNS-specific membrane protein and member of the immunoglobulin superfamily (Xu et al., 2025). The peptide segment contains dominant epitopes recognized by autoreactive T and B cells in susceptible mouse strains. Its administration models immune-driven demyelination, closely recapitulating the pathophysiology of relapsing-remitting MS (Benchmark Peptide Guide). Unlike full-length MOG, the 35-55 peptide is highly immunogenic and standardized for consistent EAE induction. This facilitates studies of autoimmune mechanisms, neuroinflammation, and preclinical therapeutic screening.

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as a potent immunogen by presenting a defined epitope to MHC class II molecules on antigen-presenting cells (APCs). Upon subcutaneous injection with complete Freund's adjuvant (CFA), the peptide is internalized and processed by dendritic cells and macrophages. The processed epitope is presented via HLA-DR2 or related murine MHC molecules, activating CD4+ T cells. These T cells secrete pro-inflammatory cytokines, recruit B cells, and drive demyelinating autoantibody production. In vivo, this results in CNS infiltration, plaque-like demyelination, and neurological deficits analogous to human MS (Xu et al., 2025). The peptide also increases NADPH oxidase and MMP-9 activities in vitro, linking to oxidative stress and extracellular matrix remodeling, which are hallmarks of neuroinflammation.

Evidence & Benchmarks

• MOG (35-55) at 50–150 μg (s.c., with CFA) induces chronic EAE and MS-like symptoms in C57BL/6 and HLA-DR2-transgenic mice, with dose-dependent severity (DOI).
• In vitro exposure to MOG (35-55) upregulates NADPH oxidase and MMP-9 activities, indicating activation of oxidative and matrix-remodeling pathways (APExBIO).
• The peptide is soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO, but insoluble in ethanol; stock solutions (0.50 mg/mL) are stable at -20°C for short-term use (APExBIO).
• Autoantibody production and T cell proliferation are reliably induced in multiple mouse strains following MOG (35-55) challenge (Mechanistic Insights).
• PARP7 inhibition, a downstream modulator in EAE models, stabilizes STAT1/STAT2 and alleviates EAE symptoms, demonstrating the model's utility for mechanistic and therapeutic studies (DOI).

Applications, Limits & Misconceptions

MOG (35-55) is the reference peptide for inducing EAE, enabling standardized preclinical MS research and therapeutic screening (Molecular Insights). It is highly effective for dissecting T and B cell responses, cytokine dynamics, and neuroinflammatory processes. However, its use has defined boundaries:

Common Pitfalls or Misconceptions

• Not effective in all species: MOG (35-55) is validated for murine and rat models; it may not recapitulate EAE in non-rodent species due to MHC restriction (Xu et al., 2025).
• Does not model progressive MS: The EAE model primarily reflects relapsing-remitting MS pathology, not progressive forms.
• Peptide instability at room temperature: Degradation occurs rapidly above 4°C or without desiccation; improper storage reduces immunogenicity (APExBIO).
• Insoluble in ethanol: Ethanol should not be used for stock preparation; only water or DMSO are validated solvents.
• Not a direct therapeutic: MOG (35-55) is a research reagent, not a candidate for clinical use or direct therapy.

This article extends existing guidance found in MOG (35-55): Optimizing Experimental Autoimmune Encephalo... by providing atomic, quantitative evidence and clarifying mechanistic boundaries, which are not detailed in protocol-oriented resources.

Workflow Integration & Parameters

Preparation: Dissolve MOG (35-55) (SKU: A8306, APExBIO) in sterile water at 0.50 mg/mL, with warming (37°C) and ultrasonic bath for complete solubilization. Avoid ethanol. For in vivo studies, aliquot and store desiccated at -20°C; use within 1 month to minimize degradation (product page).

Administration: Subcutaneously inject 50–150 μg per mouse, emulsified in CFA. Monitor for symptom onset (typically 10–14 days post-injection). Adjust dose according to strain sensitivity and study endpoints (Scenario-Driven Solutions; this article clarifies quantitative benchmarks beyond standard troubleshooting).

In Vitro Assays: Use concentrations up to 32 mg/mL in water for cell-based assays. Measure protein levels, NADPH oxidase, and MMP-9 activity to assess neuroinflammatory responses (Molecular Insights; this article specifies validated concentration ranges and solubility, which are not covered in the cited review).

Conclusion & Outlook

MOG (35-55) remains the benchmark peptide for modeling autoimmune encephalomyelitis and neuroinflammation in rodents, enabling reproducible and translational MS research. Its standardized workflow, validated by APExBIO, ensures robust induction of EAE and supports preclinical discovery—from mechanistic dissection to therapeutic intervention studies. Recent mechanistic work, such as PARP7 inhibition studies, leverages the EAE model to unravel interferon pathway regulation, underscoring the peptide's value for next-generation neuroimmunology (Xu et al., 2025).